Abstract
Background The emergence of a novel SARS-CoV-2 variant of concern called B.1.1.7 lineage sparked global alarm due to evidence of increased transmissibility, mortality, and uncertainty about vaccine efficacy, thus accelerating efforts to detect and track the variant. Current approaches to detect lineage B.1.1.7 include sequencing and RT-qPCR tests containing a target assay that fails or results in reduced sensitivity towards the B.1.1.7 variant.
Aim Since many countries lack robust genomic surveillance programs and failed assays detect multiple unrelated variants containing similar mutations as B.1.1.7, we sought to develop an RT-qPCR test that can accurately and rapidly differentiate the B.1.1.7 variant from other SARS-CoV-2 variants.
Methods We used bioinformatics, allele-specific PCR, and judicious placement of LNA-modified nucleotides to develop a test that differentiates B.1.1.7 from other SARS-CoV-2 variants. We validated the test on 106 clinical samples with lineage status confirmed by sequencing and conducted a surveillance study of B.1.1.7 lineage prevalence in Slovakia.
Results Our multiplexed RT-qPCR test showed 97% clinical sensitivity at detecting lineage B.1.1.7. The assay was used in a country-wide surveillance of B.1.1.7 lineage spread in Slovakia. Retesting nearly 7,000 SARS-CoV-2 positive samples obtained during three campaigns performed within a one month period, revealed pervasive spread of B.1.1.7 with an average prevalence of 82%.
Conclusion Labs can easily implement this test to rapidly scale B.1.1.7 surveillance efforts and it is particularly useful in countries with high prevalence of variants possessing only the ΔH69/ΔV70 deletion because current strategies using target failure assays incorrectly identify these as putative B.1.1.7 variants.
Competing Interest Statement
VK, EDP, MR, RH, and PC are employees of MultiplexDX, a biotechnology company which has commercialized a kit called rTest COVID-19 B.1.1.7 qPCR kit (https://www.multiplexdx.com/products/rtest-covid-19-b-1-1-7-qpcr-kit, MultiplexDX, Inc., Bratislava, Slovakia) that is based on this research. BK is a Head of the Department of Virus Ecology, Institute of Virology, Biomedical Research Center of the Slovak Academy of Sciences (BMC SAS). MM is a Head of the Insititute for healthcare analyses at the Slovak Ministy of Health. BMC SAS has entered into collaboration with MultiplexDX, Inc. for development and validation of RT-qPCR tests for routine detection of SARS-CoV-2 and the test for detection of B.1.1.7 variant described in this study. The Ministry of Health procured said tests for the B.1.1.7 lineage surveillance. All other authors declare no competing interests.
Funding Statement
We gratefully acknowledge the authors from the submitting and originating laboratories that shared genetic sequencing data with the GISAID initiative. We acknowledge the contribution of the oligonucleotide synthesis and production team at MultiplexDX for synthesizing the primers and probes in this study, the laboratory staff of the Slovak regional public health authorities and diagnostic laboratories for screening samples during surveillance of B.1.1.7, and the team at the Institute for Healthcare Analyses for processing the surveillance data. Surveillance of lineage B.1.1.7 using MuliplexDX tests was funded by the Ministry of Health of Slovakia. This project was supported by the European Union's Horizon 2020 research and innovation program [EVA-GLOBAL project, grant agreement number 871029] (BK) and grants from the Slovak Research and Development Agency: PP-COVID-20-0017 (BK) and PP-COVID-20-0116 (PC, BK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All clinical specimens used for clinical validation were previously collected for the purpose of primary diagnosis of SARS-CoV-2 and were made unidentifiable for the researchers performing this study. The country-wide screening was organized by the Public Health Authority of the Slovak Republic within their efforts to combat the pandemic. The B.1.1.7 RT-PCR tests were performed by the same laboratories which performed the primary diagnosis. Only the cumulative data were collected. The study has been approved by the Ethics committee of Biomedical Research Center of the Slovak Academy of Sciences, Bratislava, Slovakia (Ethics committee statement No. EK/BmV-02/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The revised version of the manuscript includes unique, country-wide surveillance data from Slovakia. The assay was used in three consecutive screening campaigns performed in two weeks intervals where all RT-PCR positive clinical samples in the country from a given day were analyzed.
Data Availability
All sequence data referred to in the manuscript are available at gisaid.org.